Japanese biotech firm Sound Wave Innovation announced a fresh capital injection of roughly 2.65 billion yen, or $16.7 million, from a syndicate that includes Singapore‑based iGlobe Partners, Fiducia and Sumitomo Heavy Industries. The funding targets the company’s ultrasound‑based therapy designed to halt or reverse Alzheimer’s pathology, a market where few disease‑modifying options exist. With the ageing population driving demand for innovative treatments.

The round, disclosed Monday, brings total raised capital to an estimated 2.65 billion yen, a sum that will finance the ongoing Phase II clinical trial slated for completion by year‑end. Investors are betting on the non‑invasive approach to breach the blood‑brain barrier, a hurdle that has limited conventional drug delivery for neurodegenerative diseases. Success would also bolster Japan’s biotech funding ecosystem, encouraging further venture inflows.

If the trial confirms safety and efficacy, Sound Wave could attract larger pharma partnerships and position Japan as a hub for ultrasound neuro‑therapeutics. The involvement of heavy‑industry player Sumitomo hints at potential manufacturing scale‑up, while iGlobe Partners presence signals growing Southeast Asian interest in Japanese med‑tech ventures. Regulators granted status, expediting review timelines, tightening the company’s runway toward a commercial launch.